CARBOCISTEINE

500 mg Capsule
MUCOLYTIC

ABLUENT®

Description of the Product
Encapsulated in hard gelatin capsule with dark green cap and light green body containing 500 mg of Carbocisteine.

What is in the Medicine?
A white or almost white, crystalline powder. Practically insoluble in water and in alcohol; dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides. A 1% suspension in water has a pH of 2.8 to 3.0. Protect from light.



Carbocisteine is rapidly and well absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 2 hours after an oral dose. It appears to penetrate into lung tissue and respiratory mucus. Carbocisteine is excreted in the urine as unchanged drug and metabolites. Acetylation, decarboxylation, and sulfoxidation have been identified as the major metabolic pathways. Sulfoxidation may be governed by genetic polymorphism.

Strength of the Medicine
Each capsule contains:
CARBOCISTEINE, BP.....500 mg

What is this medicine used for?
Carbocisteine is used in the treatment of disorder of the respiratory tract associated with excessive mucus.

How much and how often should you use this Medicine?
Adult Dose: 500 mg, one (1) capsule three (3) times daily
Or as prescribed by a physician.
To be taken orally with food.

When should you not take this Medicine?
Active peptic ulcer and known hypersensitivity to Carbocisteine.

Care that should be taken when taking this Medicine?
It is recommended that Carbocisteine be used with caution in patients with a history of peptic ulcer and be avoided in patients with active ulceration.

Undesirable Effects of this Medicine
Nausea, headache, gastric discomfort, diarrhea, gastrointestinal bleeding and skin rash have occasionally occurred with Carbocisteine.

How should you keep this Medicine?
Store at temperatures not exceeding 30°C.

Availability
Alu-Clear PVC Blister Pack x 10's (Box of 100's)

ADR Reporting Statement
"For suspected adverse drug reaction, report to the FDA:www.fda.gov.ph"
Seek medical attention immediately at the first sign of any adverse drug reaction.

Registration Number
DR-XY16987-B

Date of First Authorization/ Renewal of the Authorization
October 28, 2002

Date of Revision
SEPTEMBER 2020

Manufactured by:
JM TOLMANN LABORATORIES, INC.
#95 North Zuzuarregui St., Diliman, Q. C.

170 mm

105 mm

INSERT Required size:
170 mm x 105 mm
Required folding:
UNFOLDED